StockData
DexCom Inc logo

DexCom Inc (DXCM) stock

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.52+0.48 (+0.59%)

Close on Nov 18, 2026Market cap $30.78BP/E 32.5Yield –

DexCom operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

DexCom's operating income for the twelve months ending Sep 30, 2026 was $1.22B, up 57.4% year over year. For fiscal 2025 it was $911.80M, up 52.0% from the year before. The highest annual figure on record is $911.80M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$911.80M+52.0%
FY2024Dec 31, 2024$600.00M+0.4%
FY2023Dec 31, 2023$597.70M+52.8%
FY2022Dec 31, 2022$391.20M+47.2%
FY2021Dec 31, 2021$265.80M-11.3%
FY2020Dec 31, 2020$299.50M+110.5%
FY2019Dec 31, 2019$142.30M–
FY2018Dec 31, 2018-$186.30M–
FY2017Dec 31, 2017-$42.50M–
FY2016Dec 31, 2016-$63.90M–
FY2015Dec 31, 2015-$57.10M–
FY2014Dec 31, 2014-$21.50M–
FY2013Dec 31, 2013-$28.90M–
FY2012Dec 31, 2012-$55.70M–
FY2011Dec 31, 2011-$44.80M–
FY2010Dec 31, 2010-$45.30M–
FY2009Dec 31, 2009-$45.83M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$327.20M+34.9%
Q2 FY2026Jun 30, 2026$318.30M+49.7%
Q1 FY2026Mar 31, 2026$255.30M+90.9%
Q4 FY2025Dec 31, 2025$323.00M+71.0%
Q3 FY2025Sep 30, 2025$242.50M+59.5%
Q2 FY2025Jun 30, 2025$212.60M+34.6%
Q1 FY2025Mar 31, 2025$133.70M+32.2%
Q4 FY2024Dec 31, 2024$188.90M-12.9%
Q3 FY2024Sep 30, 2024$152.00M-26.0%
Q2 FY2024Jun 30, 2024$158.00M+23.3%
Q1 FY2024Mar 31, 2024$101.10M+114.2%
Q4 FY2023Dec 31, 2023$216.90M+73.0%
Q3 FY2023Sep 30, 2023$205.50M+39.3%
Q2 FY2023Jun 30, 2023$128.10M+66.4%
Q1 FY2023Mar 31, 2023$47.20M+14.3%
Q4 FY2022Dec 31, 2022$125.40M+20800.0%
Q3 FY2022Sep 30, 2022$147.50M+24.7%
Q2 FY2022Jun 30, 2022$77.00M-23.8%
Q1 FY2022Mar 31, 2022$41.30M-10.0%
Q4 FY2021Dec 31, 2021$600.00K-99.4%
Q3 FY2021Sep 30, 2021$118.30M+25.7%
Q2 FY2021Jun 30, 2021$101.00M+49.0%
Q1 FY2021Mar 31, 2021$45.90M+36.6%
Q4 FY2020Dec 31, 2020$104.00M+2.5%
Q3 FY2020Sep 30, 2020$94.10M+68.0%
Q2 FY2020Jun 30, 2020$67.80M–
Q1 FY2020Mar 31, 2020$33.60M–
Q4 FY2019Dec 31, 2019$101.50M–
Q3 FY2019Sep 30, 2019$56.00M+302.9%
Q2 FY2019Jun 30, 2019-$800.00K–
Q1 FY2019Mar 31, 2019-$14.40M–
Q4 FY2018Dec 31, 2018-$164.60M-1471.7%
Q3 FY2018Sep 30, 2018$13.90M–
Q2 FY2018Jun 30, 2018-$4.90M–
Q1 FY2018Mar 31, 2018-$30.70M–
Q4 FY2017Dec 31, 2017$12.00M–
Q3 FY2017Sep 30, 2017-$500.00K–
Q2 FY2017Jun 30, 2017-$13.60M–
Q1 FY2017Mar 31, 2017-$40.40M–
Q4 FY2016Dec 31, 2016-$6.10M–

More DexCom figures

See a number that looks wrong?